Navigation Links
Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response

80 patients with metastatic hormone-refractory prostate cancer (HRPC). Additional follow-up of the 22 patients who received the dose that is comparable to that being employed in the company's ongoing Phase 3 program revealed that their median survival is 35.0 months. Four patients have withdrawn consent to further follow-up and thus were censored in the analysis. The company also has previously reported final median survival results from its first multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer in 34 patients with metastatic HRPC that showed an overall median survival of 26.2 months. The survival results from the two, independent multi-center Phase 2 clinical trials compare favorably to the previously published median survival of 18.9 months for metastatic hormone-refractory prostate cancer patients treated with Taxotere(R) (docetaxel) chemotherapy plus prednisone, the current standard of care for these patients. The company's ongoing Phase 3 program is designed to confirm this potential survival benefit of GVAX immunotherapy for prostate cancer.

"The immune response data reported today provide added support for the concept that a whole-cell immunotherapy, such as GVAX immunotherapy for prostate cancer, is an ideal multi-antigen source that is capable of eliciting an immune response to a broad array of tumor-associated antigens," stated Peter K. Working, Ph.D., senior vice president of Research and Development at Cell Genesys. "That the majority of antibody responses are unique to individual patients is further evidence that the non patient-specific format of GVAX immunotherapies is capable of inducing unique, patient-specific immune responses. Moreover, the fact that many of these antigens have not before been associated with prostate cancer, further suggests that a multivalent antigen immunotherapy like GVAX immunotherapy may provide the best potential for inducing an effective anti-tumor immune response, especially for heterogeneous ca
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
2. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:3/27/2015)... Report Details  New ... companies  What does the future hold for ... Visiongain,s brand new report shows you potential revenues to ... Our 242-page report provides 185 tables, charts, and ... and the future market prospects. Our new study lets ...
(Date:3/27/2015)...   Hospira, Inc. (NYSE: HSP ... world,s leading provider of injectable drugs and infusion ... of biosimilarity of its proposed biosimilar, Epoetin Hospira, ... conditionally approved name of RETACRIT™, compared to the ... data were presented at the National Kidney Foundation ...
(Date:3/27/2015)... -- Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator ... imaging centers in China , ... under which Concord Medical Services (International) Pte Ltd, ... to acquire the Fortis Surgical Hospital from Fortis ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3
(Date:3/28/2015)... March 28, 2015 Genomic medicine experts ... mesothelioma, revealing, for the first time, key information for ... to read the newly posted story on the ... University of British Columbia, the British Columbia Cancer Agency, ... to reveal underlying molecular alterations and mutations that can ...
(Date:3/28/2015)... OR (PRWEB) March 28, 2015 Lately ... the media regarding recent changes and proposals around the ... , current and former collegiate student-athletes across a spectrum ... and reflect on common challenges. The special panel consists ... country in sports ranging from football, track and field, ...
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
(Date:3/28/2015)... 28, 2015 Designers and Professionals of ... entitled Scratches 5K from Pixel Film Studios. , “Scratches ... any media inside Final Cut Pro X” Said Christina ... time and is an effective tool for any FCPX ... Scratches 5K's intuitive grunge overlays. Simply drag title layers ...
(Date:3/28/2015)... Plainview, NY (PRWEB) March 28, 2015 ... provider of dietary supplements announces the release of ... MuffinStop™ was shown in two randomized, double-blind, placebo-controlled ... weight and waist and hip size. MuffinStop™ is ... Sphaeranthus indicus and Garcinia mangostana, fused together to ...
Breaking Medicine News(10 mins):Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2
... , ... Denver, CO (PRWEB) October 20, 2008 -- OCI, an information management ... leaders, has added two National Sales Representatives to its sales force ... and Scott Lenox, based in Chicago, Illinois., , ,“Kelly and Scott bring ...
... Dentistry awarded two gold medals in the Smile Gallery Competition to ... ... Florida (PRWEB) October 20, 2008 -- The Sarasota cosmetic ... medals from the Florida Academy of Cosmetic Dentistry,s Smile Gallery Competition., ...
... PPI class for treatment for GERD and Erosive ... ... today announced that Takeda Global Research and,Development Center, Inc., a wholly owned ... (FDA) that,the agency will not be able to complete its review of ...
... Institute of Neurological Disease (GIND) and the University of ... an enzyme that regulates fatty acid levels improves cognitive ... Their findings, which will be published in today,s issue ... that may contribute to the disease as well as ...
... Solutions, resulting from a merger between Haydon Switch ... offering its Kerk NTB anti-backlash lead screw assemblies ... The assembly,s simple, compact design offers a variety ... The Kerk NTB Series has been used ...
... could mean faster treatments for TB, fight other drug-resistant ... believe they are close to perfecting a new class ... a new study says. , The new antibiotics ... by certain bacteria to battle other bacteria -- also ...
Cached Medicine News:Health News:Employee Benefits and Risk Management Solutions Provider OCI Appoints Two New Representatives to Its Sales Team 2Health News:Sarasota Cosmetic Dentistry Practice Wins Big At FACD 2Health News:FDA Adds Three Months to Review of Takeda's New Drug Application for TAK-390MR 2Health News:Gladstone scientists identify role of fatty acids in Alzheimer's disease 2Health News:HaydonKerk Motion Solutions Now Offers Kerk NTB Series for Applications in Variety of Industries 2Health News:HaydonKerk Motion Solutions Now Offers Kerk NTB Series for Applications in Variety of Industries 3Health News:Scientists Hot on Trail of New Antibiotics 2
Iron UIBC (UIBC Buffer + Color + Std.). An Automated analyzer test kits....
HDL Cholesterol, liquid....
For the quantitative determination of high density lipoprotein (HDL) in human serum....
... the quantitative determination of ... vials, dry powder reagents. ... NADPH to eliminate interferences ... Reaction: Enzymatic, endpoint. Wavelength: ...
Medicine Products: